Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

FIX&PERM Cell Fixation and Permeabilization Kit

Flow cytometric analyses with monoclonal antibodies were so far mainly restricted to cell surface molecules. Intracellular structures such as cytoplasmic or nuclear enzymes, oncoproteins, cytokines, immunoglobulins etc. were largely excluded from such studies. Also excluded from flow cytometric studies were cytoplasmic localizations of well-established membrane molecules like CD3 and CD22, which, in their cytoplasmic form, are the most reliable lineage markers in undifferentiated leukemia. With the FIX&PERM® Kit flow cytometric analysis of intracellular antigens has become as easy as surface antigen studies. The only prerequisite is the availability of suitable antibody conjugates. Most of the available monoclonal antibody conjugates can be used with the FIX&PERM® Kit, some determinants are sensitive, however, to the fixation step involved. This and the optimal fixation time have to be tested for each reagent.

News

Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

SPARC

  • Product Code: X1860P
  • Size: 100 µg
  • Availability: In Stock In Stock
  • Price (USD): $258

Cat #

X1860P		 Quantity:      

Data Sheet

Product Name

SPARC

Synonyms

Secreted Protein Acidic and Rich in Cysteine, SPARC, SPARC-related modular calcium-binding protein 2 [Precursor], Secreted modular calcium-binding protein 2, SMOC-2, Smooth muscle-associated protein 2, SMAP-2

Host/Source

Rabbit

Isotype

IgG

Product Type

Polyclonal Antibody

Reactivity

Human SPARC, may cross react with SPARCL1

Applications

Western Blot, Immunohistochemistry, ELISA

Purification

Ammonium Sulfate Precipitation

Size

100 µg

Price (USD)

$258

Background

SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. in silico analysis reveals 4 UTR-SNPs located in the 3 -UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer. SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).

Immunogen

Synthetic peptide derived from the human SPARC protein.

Positive Control

Antibody tested on mouse heart lysate

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Target Molecular Weight

49674

Product Image

Image Legend

Detection of endogenous SPARC in mouse heart lysate using X1860P (5 ug/ml) and anti-rabbit HRP (1:75k) and using Pierce?s Super Signal West Femto.

Database Links:

SwissProtP09486Human

References

1. Shi Q, et al. 'Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.' Oncogene. 2007 Jan 8; [Epub ahead of print] PMID: 17213807

2. Aouacheria A, et al. 'In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions.' BMC Genomics. 2007 Jan 3;8(1):2 [Epub ahead of print] PMID: 17201911

3. Xue LY, et al. 'Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.'
BMC Cancer. 2006 Dec 22;6(1):296 [Epub ahead of print] PMID: 17187659

4. Arp HP, et al. 'Predicting the partitioning behavior of various highly fluorinated compounds.' Environ Sci Technol. 2006 Dec 1;40(23):7298-304. PMID: 17180981

5. Kelly KA, et al. 'SPARC is a VCAM-1 counter-ligand that mediates leukocyte transmigration.' J Leukoc Biol. 2006 Dec 18; [Epub ahead of print]

6. Markovic, S., et al. 'Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.' J. Clin. Oncol. 2010, Vol. 28, No. 15, 8578

7. Weiss, G.J., et al. 'Molecular characterization of interdigitating dendritic cell sarcoma.' Rare Tumors, 2010, 2:e50

8. Alonso, E.N., et al. ?Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells.? J. Med. Food., 16, 602-617 (2013).